Thymosin Alpha-1
Definition: An immunomodulatory peptide that enhances the body's natural defense mechanisms against chronic infections and certain cancers.
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1), clinically known as Thymalfasin, is a synthetic version of a naturally occurring 28-amino acid peptide produced by the thymus gland. Tα1 plays a fundamental role in maintaining immune homeostasis, stimulating T-cell production, and modulating the body's response to viral infections, bacterial pathogens, and malignancies.
How does Thymosin Alpha-1 work?
Tα1 acts as an immunomodulator. It binds to Toll-Like Receptors (TLRs) on immune cells, triggering the maturation and activation of T-cells, dendritic cells, and natural killer (NK) cells. It selectively promotes the release of pro-inflammatory cytokines (like IFN-gamma and IL-2) during active infection, while upregulating anti-inflammatory cytokines (like IL-10) to prevent immune system overactivation or cytokine storms.
Primary Documented Uses
- Supporting immune function in chronic viral infections (Hepatitis, HIV, EBV)
- Adjuvant therapy in cancer treatment to boost white blood cell counts
- Enhancing vaccine efficacy in immunocompromised individuals
- Modulating autoimmune responses and reducing chronic inflammation
Research Summary
Thymosin Alpha-1 is backed by extensive international clinical use and research. It is approved in over 30 countries for the treatment of Hepatitis B and C, and as an adjuvant to chemotherapy. During the COVID-19 pandemic, multiple clinical trials evaluated its role in reducing mortality in severe cases by restoring T-cell counts. It is widely recognized for its high safety profile and low incidence of adverse effects.
Legal and Regulatory Status
Thymosin Alpha-1 is approved as an orphan drug in the US for specific conditions (such as Hepatitis B) and is widely approved internationally under the name Zadaxin. However, in late 2023, the FDA placed it on the Category 2 bulk drug substances list, restricting compounding pharmacies from distributing it as a general wellness compounded therapy. It remains available for approved medical uses and as a research chemical.
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 is An immunomodulatory peptide that enhances the body's natural defense mechanisms against chronic infections and certain cancers.
How does Thymosin Alpha-1 work?
Tα1 acts as an immunomodulator. It binds to Toll-Like Receptors (TLRs) on immune cells, triggering the maturation and activation of T-cells, dendritic cells, and natural killer (NK) cells. It selectively promotes the release of pro-inflammatory cytokines (like IFN-gamma and IL-2) during active infection, while upregulating anti-inflammatory cytokines (like IL-10) to prevent immune system overactivation or cytokine storms.
What does research say about Thymosin Alpha-1?
Thymosin Alpha-1 is backed by extensive international clinical use and research. It is approved in over 30 countries for the treatment of Hepatitis B and C, and as an adjuvant to chemotherapy. During the COVID-19 pandemic, multiple clinical trials evaluated its role in reducing mortality in severe cases by restoring T-cell counts. It is widely recognized for its high safety profile and low incidence of adverse effects.
Is Thymosin Alpha-1 FDA-approved or legally available?
Thymosin Alpha-1 is approved as an orphan drug in the US for specific conditions (such as Hepatitis B) and is widely approved internationally under the name Zadaxin. However, in late 2023, the FDA placed it on the Category 2 bulk drug substances list, restricting compounding pharmacies from distributing it as a general wellness compounded therapy. It remains available for approved medical uses and as a research chemical.